Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allan Gibofsky

Rheumatology New York, NY Medical Doctor

NPI 1467500611 CMS profile 156579

535 E 70Th St, New York, NY 10021

Open in the dashboard

General payments

$1,876,062

1,324 records reported · program years 2019–2025

Research payments

$6,480

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allan Gibofsky of New York, NY is reported in the CMS Open Payments database as having received $1,876,062 across 1,324 general payments and $6,480 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180,110 256
2024 General $126,503 187
2023 General $104,550 153
2023 Research $3,980 2
2022 General $88,364 128
2022 Research $500 1
2021 General $365,213 49
2020 General $520,290 107
2020 Research $2,000 1
2019 General $491,033 444

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allan Gibofsky
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Allan Gibofsky were reported at $180,110. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Allan Gibofsky Rheumatology median Middle half National median
2019 $491,033 $744 $153–$2,687 $163
2020 $520,290 $462 $98–$2,027 $114
2021 $365,213 $531 $101–$2,153 $132
2022 $88,364 $627 $125–$2,303 $149
2023 $104,550 $741 $145–$2,524 $160
2024 $126,503 $830 $166–$2,660 $164
2025 $180,110 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Scientific Affairs, LLC $776,322 149 payments
  2. AbbVie, Inc. $418,745 392 payments
  3. Pfizer Inc. $198,506 212 payments
  4. UCB, Inc. $112,436 124 payments
  5. Lilly USA, LLC $100,361 131 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $56,421 13 payments
  7. Novartis Pharmaceuticals Corporation $48,432 112 payments
  8. United Rheumatology $28,750 4 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $28,153 16 payments
  10. Amgen Inc. $25,291 17 payments
  11. Other $82,646 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,064,619 98 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $591,001 213 payments
  3. Travel and Lodging $143,121 495 payments
  4. Honoraria $35,292 32 payments
  5. Grant $25,000 1 payment
  6. Food and Beverage $16,999 481 payments
  7. Education $29 4 payments
Products named General payments · program years 2019–2025
  1. SIMPONI ARIA $751,531 15 payments
  2. RINVOQ Immunology $200,430 197 payments
  3. XELJANZ $143,931 138 payments
  4. Bimzelx $104,761 107 payments
  5. OLUMIANT $81,987 60 payments
  6. HUMIRA $44,538 50 payments
  7. RINVOQ Immunology $36,183 29 payments
  8. Uloric $28,153 16 payments
  9. COSENTYX $26,215 35 payments
  10. TREMFYA $24,790 134 payments
  11. Other $128,925 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $3,980 2 payments
  2. AbbVie, Inc. $2,500 2 payments

Records

1,328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record